nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—CYP3A4—bone cancer	0.367	1	CbGaD
Haloperidol—CBR1—Doxorubicin—bone cancer	0.311	0.789	CbGbCtD
Haloperidol—CYP2C9—Cisplatin—bone cancer	0.0196	0.0496	CbGbCtD
Haloperidol—ABCB1—Cisplatin—bone cancer	0.019	0.0481	CbGbCtD
Haloperidol—ABCB1—Doxorubicin—bone cancer	0.0127	0.0323	CbGbCtD
Haloperidol—ABCB1—Methotrexate—bone cancer	0.0123	0.0312	CbGbCtD
Haloperidol—CYP2D6—Doxorubicin—bone cancer	0.012	0.0304	CbGbCtD
Haloperidol—HTR1B—dura mater—bone cancer	0.0111	0.183	CbGeAlD
Haloperidol—HTR1D—dura mater—bone cancer	0.0107	0.177	CbGeAlD
Haloperidol—CYP3A4—Doxorubicin—bone cancer	0.00762	0.0193	CbGbCtD
Haloperidol—HTR1B—trigeminal nerve—bone cancer	0.00476	0.0788	CbGeAlD
Haloperidol—HTR1D—trigeminal nerve—bone cancer	0.0046	0.0763	CbGeAlD
Haloperidol—HRH1—nose—bone cancer	0.00349	0.0578	CbGeAlD
Haloperidol—HTR1B—cranial nerve—bone cancer	0.00339	0.0561	CbGeAlD
Haloperidol—HTR1D—cranial nerve—bone cancer	0.00328	0.0543	CbGeAlD
Haloperidol—HTR2A—trigeminal nerve—bone cancer	0.00229	0.0379	CbGeAlD
Haloperidol—HTR2A—cranial nerve—bone cancer	0.00163	0.027	CbGeAlD
Haloperidol—HTR2A—vertebral column—bone cancer	0.0016	0.0265	CbGeAlD
Haloperidol—HTR2A—hindlimb—bone cancer	0.00137	0.0228	CbGeAlD
Haloperidol—HTR2A—appendage—bone cancer	0.00118	0.0195	CbGeAlD
Haloperidol—GRIN2B—spinal cord—bone cancer	0.000953	0.0158	CbGeAlD
Haloperidol—H1F0—connective tissue—bone cancer	0.000874	0.0145	CbGeAlD
Haloperidol—CBR1—tendon—bone cancer	0.000733	0.0121	CbGeAlD
Haloperidol—CBR1—bone marrow—bone cancer	0.00071	0.0118	CbGeAlD
Haloperidol—CBR1—spinal cord—bone cancer	0.000707	0.0117	CbGeAlD
Haloperidol—HTR1D—connective tissue—bone cancer	0.000677	0.0112	CbGeAlD
Haloperidol—H1F0—tendon—bone cancer	0.000601	0.00995	CbGeAlD
Haloperidol—H1F0—bone marrow—bone cancer	0.000582	0.00964	CbGeAlD
Haloperidol—H1F0—spinal cord—bone cancer	0.000579	0.0096	CbGeAlD
Haloperidol—HTR1B—spinal cord—bone cancer	0.000463	0.00768	CbGeAlD
Haloperidol—SIGMAR1—tendon—bone cancer	0.000434	0.00719	CbGeAlD
Haloperidol—HTR2B—tendon—bone cancer	0.000433	0.00717	CbGeAlD
Haloperidol—SIGMAR1—bone marrow—bone cancer	0.00042	0.00696	CbGeAlD
Haloperidol—Gynaecomastia—Methotrexate—bone cancer	0.000419	0.00528	CcSEcCtD
Haloperidol—SIGMAR1—spinal cord—bone cancer	0.000418	0.00693	CbGeAlD
Haloperidol—Gait disturbance—Doxorubicin—bone cancer	0.000415	0.00523	CcSEcCtD
Haloperidol—Visual impairment—Cisplatin—bone cancer	0.000413	0.0052	CcSEcCtD
Haloperidol—Ventricular tachycardia—Doxorubicin—bone cancer	0.000405	0.00511	CcSEcCtD
Haloperidol—Injection site reaction—Doxorubicin—bone cancer	0.000403	0.00508	CcSEcCtD
Haloperidol—HRH1—connective tissue—bone cancer	0.000403	0.00667	CbGeAlD
Haloperidol—Eye disorder—Cisplatin—bone cancer	0.0004	0.00504	CcSEcCtD
Haloperidol—Cardiac disorder—Cisplatin—bone cancer	0.000398	0.00501	CcSEcCtD
Haloperidol—Salivary hypersecretion—Doxorubicin—bone cancer	0.000394	0.00496	CcSEcCtD
Haloperidol—Photosensitivity—Methotrexate—bone cancer	0.000387	0.00488	CcSEcCtD
Haloperidol—Immune system disorder—Cisplatin—bone cancer	0.000387	0.00488	CcSEcCtD
Haloperidol—Mediastinal disorder—Cisplatin—bone cancer	0.000386	0.00487	CcSEcCtD
Haloperidol—Hypertonia—Epirubicin—bone cancer	0.000384	0.00484	CcSEcCtD
Haloperidol—Alopecia—Cisplatin—bone cancer	0.000379	0.00477	CcSEcCtD
Haloperidol—Malnutrition—Cisplatin—bone cancer	0.000373	0.0047	CcSEcCtD
Haloperidol—Hepatic function abnormal—Epirubicin—bone cancer	0.000364	0.00459	CcSEcCtD
Haloperidol—Photosensitivity—Epirubicin—bone cancer	0.000362	0.00456	CcSEcCtD
Haloperidol—Dermatitis exfoliative—Methotrexate—bone cancer	0.00036	0.00454	CcSEcCtD
Haloperidol—Visual disturbance—Methotrexate—bone cancer	0.000359	0.00452	CcSEcCtD
Haloperidol—Muscle spasms—Cisplatin—bone cancer	0.000359	0.00452	CcSEcCtD
Haloperidol—Hypertonia—Doxorubicin—bone cancer	0.000355	0.00448	CcSEcCtD
Haloperidol—Vision blurred—Cisplatin—bone cancer	0.000351	0.00443	CcSEcCtD
Haloperidol—Tremor—Cisplatin—bone cancer	0.000349	0.0044	CcSEcCtD
Haloperidol—Lethargy—Methotrexate—bone cancer	0.000347	0.00437	CcSEcCtD
Haloperidol—Anaemia—Cisplatin—bone cancer	0.000345	0.00434	CcSEcCtD
Haloperidol—Dermatitis exfoliative—Epirubicin—bone cancer	0.000337	0.00425	CcSEcCtD
Haloperidol—Hepatic function abnormal—Doxorubicin—bone cancer	0.000337	0.00424	CcSEcCtD
Haloperidol—HTR2A—connective tissue—bone cancer	0.000336	0.00557	CbGeAlD
Haloperidol—Photosensitivity—Doxorubicin—bone cancer	0.000335	0.00422	CcSEcCtD
Haloperidol—KCNH2—bone marrow—bone cancer	0.000334	0.00554	CbGeAlD
Haloperidol—Leukopenia—Cisplatin—bone cancer	0.000334	0.00421	CcSEcCtD
Haloperidol—KCNH2—spinal cord—bone cancer	0.000333	0.00552	CbGeAlD
Haloperidol—Hypoglycaemia—Epirubicin—bone cancer	0.000326	0.00411	CcSEcCtD
Haloperidol—Lethargy—Epirubicin—bone cancer	0.000325	0.00409	CcSEcCtD
Haloperidol—Convulsion—Cisplatin—bone cancer	0.000323	0.00407	CcSEcCtD
Haloperidol—Hyponatraemia—Epirubicin—bone cancer	0.000319	0.00402	CcSEcCtD
Haloperidol—Anxiety—Cisplatin—bone cancer	0.000316	0.00399	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000315	0.00397	CcSEcCtD
Haloperidol—Liver function test abnormal—Methotrexate—bone cancer	0.000314	0.00395	CcSEcCtD
Haloperidol—Dermatitis exfoliative—Doxorubicin—bone cancer	0.000312	0.00393	CcSEcCtD
Haloperidol—Breast disorder—Methotrexate—bone cancer	0.000307	0.00387	CcSEcCtD
Haloperidol—Face oedema—Epirubicin—bone cancer	0.000307	0.00387	CcSEcCtD
Haloperidol—Anaphylactic shock—Cisplatin—bone cancer	0.000304	0.00384	CcSEcCtD
Haloperidol—Oedema—Cisplatin—bone cancer	0.000304	0.00384	CcSEcCtD
Haloperidol—Cardiac arrest—Epirubicin—bone cancer	0.000302	0.00381	CcSEcCtD
Haloperidol—Hypoglycaemia—Doxorubicin—bone cancer	0.000302	0.0038	CcSEcCtD
Haloperidol—Lethargy—Doxorubicin—bone cancer	0.0003	0.00378	CcSEcCtD
Haloperidol—Nervous system disorder—Cisplatin—bone cancer	0.000299	0.00376	CcSEcCtD
Haloperidol—Thrombocytopenia—Cisplatin—bone cancer	0.000298	0.00376	CcSEcCtD
Haloperidol—Tachycardia—Cisplatin—bone cancer	0.000297	0.00374	CcSEcCtD
Haloperidol—Skin disorder—Cisplatin—bone cancer	0.000296	0.00373	CcSEcCtD
Haloperidol—Hyponatraemia—Doxorubicin—bone cancer	0.000295	0.00372	CcSEcCtD
Haloperidol—Hyperhidrosis—Cisplatin—bone cancer	0.000294	0.00371	CcSEcCtD
Haloperidol—Liver function test abnormal—Epirubicin—bone cancer	0.000294	0.0037	CcSEcCtD
Haloperidol—Orthostatic hypotension—Epirubicin—bone cancer	0.00029	0.00366	CcSEcCtD
Haloperidol—Anorexia—Cisplatin—bone cancer	0.00029	0.00366	CcSEcCtD
Haloperidol—Breast disorder—Epirubicin—bone cancer	0.000287	0.00362	CcSEcCtD
Haloperidol—Hypotension—Cisplatin—bone cancer	0.000284	0.00358	CcSEcCtD
Haloperidol—Face oedema—Doxorubicin—bone cancer	0.000284	0.00358	CcSEcCtD
Haloperidol—Cardiac arrest—Doxorubicin—bone cancer	0.00028	0.00353	CcSEcCtD
Haloperidol—Pancytopenia—Methotrexate—bone cancer	0.000279	0.00351	CcSEcCtD
Haloperidol—HRH1—tendon—bone cancer	0.000277	0.00458	CbGeAlD
Haloperidol—Dysphagia—Epirubicin—bone cancer	0.000275	0.00346	CcSEcCtD
Haloperidol—Neutropenia—Methotrexate—bone cancer	0.000275	0.00346	CcSEcCtD
Haloperidol—Liver function test abnormal—Doxorubicin—bone cancer	0.000272	0.00342	CcSEcCtD
Haloperidol—Dyspnoea—Cisplatin—bone cancer	0.000271	0.00342	CcSEcCtD
Haloperidol—Erectile dysfunction—Methotrexate—bone cancer	0.000271	0.00341	CcSEcCtD
Haloperidol—Orthostatic hypotension—Doxorubicin—bone cancer	0.000269	0.00339	CcSEcCtD
Haloperidol—Photosensitivity reaction—Methotrexate—bone cancer	0.000268	0.00338	CcSEcCtD
Haloperidol—Breast disorder—Doxorubicin—bone cancer	0.000266	0.00335	CcSEcCtD
Haloperidol—Decreased appetite—Cisplatin—bone cancer	0.000265	0.00333	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Cisplatin—bone cancer	0.000263	0.00331	CcSEcCtD
Haloperidol—Drowsiness—Methotrexate—bone cancer	0.000262	0.0033	CcSEcCtD
Haloperidol—Depression—Methotrexate—bone cancer	0.000261	0.00329	CcSEcCtD
Haloperidol—Pancytopenia—Epirubicin—bone cancer	0.000261	0.00329	CcSEcCtD
Haloperidol—Neutropenia—Epirubicin—bone cancer	0.000257	0.00324	CcSEcCtD
Haloperidol—Dysphagia—Doxorubicin—bone cancer	0.000254	0.0032	CcSEcCtD
Haloperidol—Photosensitivity reaction—Epirubicin—bone cancer	0.000251	0.00316	CcSEcCtD
Haloperidol—Feeling abnormal—Cisplatin—bone cancer	0.000251	0.00316	CcSEcCtD
Haloperidol—Weight increased—Epirubicin—bone cancer	0.00025	0.00315	CcSEcCtD
Haloperidol—Weight decreased—Epirubicin—bone cancer	0.000249	0.00313	CcSEcCtD
Haloperidol—Hyperglycaemia—Epirubicin—bone cancer	0.000248	0.00312	CcSEcCtD
Haloperidol—Hepatobiliary disease—Methotrexate—bone cancer	0.000248	0.00312	CcSEcCtD
Haloperidol—Drowsiness—Epirubicin—bone cancer	0.000245	0.00309	CcSEcCtD
Haloperidol—Agranulocytosis—Methotrexate—bone cancer	0.000244	0.00308	CcSEcCtD
Haloperidol—Pancytopenia—Doxorubicin—bone cancer	0.000242	0.00304	CcSEcCtD
Haloperidol—Body temperature increased—Cisplatin—bone cancer	0.000241	0.00303	CcSEcCtD
Haloperidol—Jaundice—Epirubicin—bone cancer	0.000239	0.00301	CcSEcCtD
Haloperidol—Neutropenia—Doxorubicin—bone cancer	0.000238	0.003	CcSEcCtD
Haloperidol—Hepatitis—Methotrexate—bone cancer	0.000235	0.00296	CcSEcCtD
Haloperidol—Urinary tract disorder—Methotrexate—bone cancer	0.000232	0.00293	CcSEcCtD
Haloperidol—Photosensitivity reaction—Doxorubicin—bone cancer	0.000232	0.00293	CcSEcCtD
Haloperidol—Hepatobiliary disease—Epirubicin—bone cancer	0.000232	0.00292	CcSEcCtD
Haloperidol—Weight increased—Doxorubicin—bone cancer	0.000231	0.00292	CcSEcCtD
Haloperidol—HTR2A—tendon—bone cancer	0.000231	0.00383	CbGeAlD
Haloperidol—Urethral disorder—Methotrexate—bone cancer	0.00023	0.0029	CcSEcCtD
Haloperidol—Weight decreased—Doxorubicin—bone cancer	0.00023	0.0029	CcSEcCtD
Haloperidol—Hyperglycaemia—Doxorubicin—bone cancer	0.000229	0.00289	CcSEcCtD
Haloperidol—Agranulocytosis—Epirubicin—bone cancer	0.000229	0.00288	CcSEcCtD
Haloperidol—Drowsiness—Doxorubicin—bone cancer	0.000227	0.00286	CcSEcCtD
Haloperidol—Visual impairment—Methotrexate—bone cancer	0.000227	0.00285	CcSEcCtD
Haloperidol—Hypersensitivity—Cisplatin—bone cancer	0.000224	0.00283	CcSEcCtD
Haloperidol—HTR2A—spinal cord—bone cancer	0.000223	0.00369	CbGeAlD
Haloperidol—Jaundice—Doxorubicin—bone cancer	0.000221	0.00279	CcSEcCtD
Haloperidol—Hepatitis—Epirubicin—bone cancer	0.00022	0.00277	CcSEcCtD
Haloperidol—Eye disorder—Methotrexate—bone cancer	0.00022	0.00277	CcSEcCtD
Haloperidol—Cardiac disorder—Methotrexate—bone cancer	0.000218	0.00275	CcSEcCtD
Haloperidol—Urinary tract disorder—Epirubicin—bone cancer	0.000217	0.00274	CcSEcCtD
Haloperidol—Connective tissue disorder—Epirubicin—bone cancer	0.000216	0.00272	CcSEcCtD
Haloperidol—Urethral disorder—Epirubicin—bone cancer	0.000216	0.00272	CcSEcCtD
Haloperidol—Hepatobiliary disease—Doxorubicin—bone cancer	0.000214	0.0027	CcSEcCtD
Haloperidol—Angiopathy—Methotrexate—bone cancer	0.000213	0.00269	CcSEcCtD
Haloperidol—Immune system disorder—Methotrexate—bone cancer	0.000212	0.00268	CcSEcCtD
Haloperidol—Visual impairment—Epirubicin—bone cancer	0.000212	0.00267	CcSEcCtD
Haloperidol—Mediastinal disorder—Methotrexate—bone cancer	0.000212	0.00267	CcSEcCtD
Haloperidol—Agranulocytosis—Doxorubicin—bone cancer	0.000212	0.00267	CcSEcCtD
Haloperidol—Diarrhoea—Cisplatin—bone cancer	0.000208	0.00262	CcSEcCtD
Haloperidol—Alopecia—Methotrexate—bone cancer	0.000208	0.00262	CcSEcCtD
Haloperidol—Mental disorder—Methotrexate—bone cancer	0.000206	0.0026	CcSEcCtD
Haloperidol—Eye disorder—Epirubicin—bone cancer	0.000206	0.00259	CcSEcCtD
Haloperidol—Malnutrition—Methotrexate—bone cancer	0.000205	0.00258	CcSEcCtD
Haloperidol—Cardiac disorder—Epirubicin—bone cancer	0.000204	0.00257	CcSEcCtD
Haloperidol—Hepatitis—Doxorubicin—bone cancer	0.000204	0.00257	CcSEcCtD
Haloperidol—Urinary tract disorder—Doxorubicin—bone cancer	0.000201	0.00253	CcSEcCtD
Haloperidol—Connective tissue disorder—Doxorubicin—bone cancer	0.0002	0.00252	CcSEcCtD
Haloperidol—Angiopathy—Epirubicin—bone cancer	0.0002	0.00252	CcSEcCtD
Haloperidol—Urethral disorder—Doxorubicin—bone cancer	0.0002	0.00251	CcSEcCtD
Haloperidol—Immune system disorder—Epirubicin—bone cancer	0.000199	0.0025	CcSEcCtD
Haloperidol—Mediastinal disorder—Epirubicin—bone cancer	0.000198	0.0025	CcSEcCtD
Haloperidol—Visual impairment—Doxorubicin—bone cancer	0.000196	0.00247	CcSEcCtD
Haloperidol—Alopecia—Epirubicin—bone cancer	0.000194	0.00245	CcSEcCtD
Haloperidol—Vomiting—Cisplatin—bone cancer	0.000194	0.00244	CcSEcCtD
Haloperidol—Vision blurred—Methotrexate—bone cancer	0.000193	0.00243	CcSEcCtD
Haloperidol—Mental disorder—Epirubicin—bone cancer	0.000193	0.00243	CcSEcCtD
Haloperidol—Rash—Cisplatin—bone cancer	0.000192	0.00242	CcSEcCtD
Haloperidol—Dermatitis—Cisplatin—bone cancer	0.000192	0.00242	CcSEcCtD
Haloperidol—Malnutrition—Epirubicin—bone cancer	0.000192	0.00241	CcSEcCtD
Haloperidol—Eye disorder—Doxorubicin—bone cancer	0.00019	0.0024	CcSEcCtD
Haloperidol—Anaemia—Methotrexate—bone cancer	0.000189	0.00238	CcSEcCtD
Haloperidol—Cardiac disorder—Doxorubicin—bone cancer	0.000189	0.00238	CcSEcCtD
Haloperidol—Angiopathy—Doxorubicin—bone cancer	0.000185	0.00233	CcSEcCtD
Haloperidol—Muscle spasms—Epirubicin—bone cancer	0.000184	0.00232	CcSEcCtD
Haloperidol—Immune system disorder—Doxorubicin—bone cancer	0.000184	0.00232	CcSEcCtD
Haloperidol—Vertigo—Methotrexate—bone cancer	0.000184	0.00232	CcSEcCtD
Haloperidol—Mediastinal disorder—Doxorubicin—bone cancer	0.000183	0.00231	CcSEcCtD
Haloperidol—Leukopenia—Methotrexate—bone cancer	0.000183	0.00231	CcSEcCtD
Haloperidol—Sertindole—CYP3A4—bone cancer	0.000182	0.663	CrCbGaD
Haloperidol—Nausea—Cisplatin—bone cancer	0.000181	0.00228	CcSEcCtD
Haloperidol—Vision blurred—Epirubicin—bone cancer	0.000181	0.00227	CcSEcCtD
Haloperidol—Alopecia—Doxorubicin—bone cancer	0.00018	0.00227	CcSEcCtD
Haloperidol—Mental disorder—Doxorubicin—bone cancer	0.000178	0.00225	CcSEcCtD
Haloperidol—Convulsion—Methotrexate—bone cancer	0.000177	0.00223	CcSEcCtD
Haloperidol—Malnutrition—Doxorubicin—bone cancer	0.000177	0.00223	CcSEcCtD
Haloperidol—Anaemia—Epirubicin—bone cancer	0.000177	0.00223	CcSEcCtD
Haloperidol—Agitation—Epirubicin—bone cancer	0.000176	0.00222	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000173	0.00218	CcSEcCtD
Haloperidol—Vertigo—Epirubicin—bone cancer	0.000172	0.00217	CcSEcCtD
Haloperidol—Leukopenia—Epirubicin—bone cancer	0.000171	0.00216	CcSEcCtD
Haloperidol—Muscle spasms—Doxorubicin—bone cancer	0.00017	0.00215	CcSEcCtD
Haloperidol—Confusional state—Methotrexate—bone cancer	0.000168	0.00212	CcSEcCtD
Haloperidol—Anaphylactic shock—Methotrexate—bone cancer	0.000167	0.0021	CcSEcCtD
Haloperidol—Vision blurred—Doxorubicin—bone cancer	0.000167	0.0021	CcSEcCtD
Haloperidol—Convulsion—Epirubicin—bone cancer	0.000166	0.00209	CcSEcCtD
Haloperidol—Hypertension—Epirubicin—bone cancer	0.000165	0.00208	CcSEcCtD
Haloperidol—Nervous system disorder—Methotrexate—bone cancer	0.000164	0.00206	CcSEcCtD
Haloperidol—Anaemia—Doxorubicin—bone cancer	0.000164	0.00206	CcSEcCtD
Haloperidol—Thrombocytopenia—Methotrexate—bone cancer	0.000164	0.00206	CcSEcCtD
Haloperidol—Agitation—Doxorubicin—bone cancer	0.000163	0.00205	CcSEcCtD
Haloperidol—Anxiety—Epirubicin—bone cancer	0.000162	0.00205	CcSEcCtD
Haloperidol—Skin disorder—Methotrexate—bone cancer	0.000162	0.00204	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000162	0.00204	CcSEcCtD
Haloperidol—Hyperhidrosis—Methotrexate—bone cancer	0.000161	0.00203	CcSEcCtD
Haloperidol—Dry mouth—Epirubicin—bone cancer	0.000159	0.00201	CcSEcCtD
Haloperidol—Vertigo—Doxorubicin—bone cancer	0.000159	0.00201	CcSEcCtD
Haloperidol—Anorexia—Methotrexate—bone cancer	0.000159	0.00201	CcSEcCtD
Haloperidol—Leukopenia—Doxorubicin—bone cancer	0.000159	0.002	CcSEcCtD
Haloperidol—Confusional state—Epirubicin—bone cancer	0.000158	0.00199	CcSEcCtD
Haloperidol—Oedema—Epirubicin—bone cancer	0.000156	0.00197	CcSEcCtD
Haloperidol—Anaphylactic shock—Epirubicin—bone cancer	0.000156	0.00197	CcSEcCtD
Haloperidol—Hypotension—Methotrexate—bone cancer	0.000156	0.00197	CcSEcCtD
Haloperidol—Convulsion—Doxorubicin—bone cancer	0.000154	0.00193	CcSEcCtD
Haloperidol—Nervous system disorder—Epirubicin—bone cancer	0.000153	0.00193	CcSEcCtD
Haloperidol—Thrombocytopenia—Epirubicin—bone cancer	0.000153	0.00193	CcSEcCtD
Haloperidol—Hypertension—Doxorubicin—bone cancer	0.000153	0.00193	CcSEcCtD
Haloperidol—Tachycardia—Epirubicin—bone cancer	0.000153	0.00192	CcSEcCtD
Haloperidol—Skin disorder—Epirubicin—bone cancer	0.000152	0.00191	CcSEcCtD
Haloperidol—Hyperhidrosis—Epirubicin—bone cancer	0.000151	0.0019	CcSEcCtD
Haloperidol—Insomnia—Methotrexate—bone cancer	0.000151	0.0019	CcSEcCtD
Haloperidol—Anxiety—Doxorubicin—bone cancer	0.00015	0.00189	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00015	0.00189	CcSEcCtD
Haloperidol—Anorexia—Epirubicin—bone cancer	0.000149	0.00188	CcSEcCtD
Haloperidol—Dyspnoea—Methotrexate—bone cancer	0.000149	0.00188	CcSEcCtD
Haloperidol—Somnolence—Methotrexate—bone cancer	0.000148	0.00187	CcSEcCtD
Haloperidol—Dry mouth—Doxorubicin—bone cancer	0.000148	0.00186	CcSEcCtD
Haloperidol—Dyspepsia—Methotrexate—bone cancer	0.000147	0.00185	CcSEcCtD
Haloperidol—ABCB1—bone marrow—bone cancer	0.000147	0.00243	CbGeAlD
Haloperidol—ABCB1—spinal cord—bone cancer	0.000146	0.00242	CbGeAlD
Haloperidol—Hypotension—Epirubicin—bone cancer	0.000146	0.00184	CcSEcCtD
Haloperidol—Confusional state—Doxorubicin—bone cancer	0.000146	0.00184	CcSEcCtD
Haloperidol—Decreased appetite—Methotrexate—bone cancer	0.000145	0.00183	CcSEcCtD
Haloperidol—Anaphylactic shock—Doxorubicin—bone cancer	0.000145	0.00182	CcSEcCtD
Haloperidol—Oedema—Doxorubicin—bone cancer	0.000145	0.00182	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Methotrexate—bone cancer	0.000144	0.00182	CcSEcCtD
Haloperidol—Nervous system disorder—Doxorubicin—bone cancer	0.000142	0.00179	CcSEcCtD
Haloperidol—Thrombocytopenia—Doxorubicin—bone cancer	0.000142	0.00178	CcSEcCtD
Haloperidol—Insomnia—Epirubicin—bone cancer	0.000141	0.00178	CcSEcCtD
Haloperidol—Tachycardia—Doxorubicin—bone cancer	0.000141	0.00178	CcSEcCtD
Haloperidol—Skin disorder—Doxorubicin—bone cancer	0.00014	0.00177	CcSEcCtD
Haloperidol—Hyperhidrosis—Doxorubicin—bone cancer	0.00014	0.00176	CcSEcCtD
Haloperidol—Dyspnoea—Epirubicin—bone cancer	0.000139	0.00176	CcSEcCtD
Haloperidol—Somnolence—Epirubicin—bone cancer	0.000139	0.00175	CcSEcCtD
Haloperidol—Anorexia—Doxorubicin—bone cancer	0.000138	0.00174	CcSEcCtD
Haloperidol—Feeling abnormal—Methotrexate—bone cancer	0.000138	0.00173	CcSEcCtD
Haloperidol—Dyspepsia—Epirubicin—bone cancer	0.000138	0.00173	CcSEcCtD
Haloperidol—Decreased appetite—Epirubicin—bone cancer	0.000136	0.00171	CcSEcCtD
Haloperidol—Hypotension—Doxorubicin—bone cancer	0.000135	0.0017	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Epirubicin—bone cancer	0.000135	0.0017	CcSEcCtD
Haloperidol—Constipation—Epirubicin—bone cancer	0.000134	0.00168	CcSEcCtD
Haloperidol—Urticaria—Methotrexate—bone cancer	0.000133	0.00167	CcSEcCtD
Haloperidol—Body temperature increased—Methotrexate—bone cancer	0.000132	0.00166	CcSEcCtD
Haloperidol—Insomnia—Doxorubicin—bone cancer	0.000131	0.00165	CcSEcCtD
Haloperidol—Dyspnoea—Doxorubicin—bone cancer	0.000129	0.00162	CcSEcCtD
Haloperidol—Feeling abnormal—Epirubicin—bone cancer	0.000129	0.00162	CcSEcCtD
Haloperidol—Somnolence—Doxorubicin—bone cancer	0.000129	0.00162	CcSEcCtD
Haloperidol—Dyspepsia—Doxorubicin—bone cancer	0.000127	0.0016	CcSEcCtD
Haloperidol—Decreased appetite—Doxorubicin—bone cancer	0.000126	0.00158	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000125	0.00157	CcSEcCtD
Haloperidol—Urticaria—Epirubicin—bone cancer	0.000124	0.00156	CcSEcCtD
Haloperidol—Constipation—Doxorubicin—bone cancer	0.000124	0.00156	CcSEcCtD
Haloperidol—Body temperature increased—Epirubicin—bone cancer	0.000124	0.00156	CcSEcCtD
Haloperidol—Hypersensitivity—Methotrexate—bone cancer	0.000123	0.00155	CcSEcCtD
Haloperidol—Feeling abnormal—Doxorubicin—bone cancer	0.000119	0.0015	CcSEcCtD
Haloperidol—Pruritus—Methotrexate—bone cancer	0.000118	0.00149	CcSEcCtD
Haloperidol—Hypersensitivity—Epirubicin—bone cancer	0.000115	0.00145	CcSEcCtD
Haloperidol—Urticaria—Doxorubicin—bone cancer	0.000115	0.00145	CcSEcCtD
Haloperidol—Body temperature increased—Doxorubicin—bone cancer	0.000114	0.00144	CcSEcCtD
Haloperidol—Diarrhoea—Methotrexate—bone cancer	0.000114	0.00144	CcSEcCtD
Haloperidol—Pruritus—Epirubicin—bone cancer	0.000111	0.00139	CcSEcCtD
Haloperidol—Dizziness—Methotrexate—bone cancer	0.00011	0.00139	CcSEcCtD
Haloperidol—Diarrhoea—Epirubicin—bone cancer	0.000107	0.00135	CcSEcCtD
Haloperidol—Hypersensitivity—Doxorubicin—bone cancer	0.000107	0.00134	CcSEcCtD
Haloperidol—Vomiting—Methotrexate—bone cancer	0.000106	0.00134	CcSEcCtD
Haloperidol—Rash—Methotrexate—bone cancer	0.000105	0.00133	CcSEcCtD
Haloperidol—Dermatitis—Methotrexate—bone cancer	0.000105	0.00133	CcSEcCtD
Haloperidol—Headache—Methotrexate—bone cancer	0.000105	0.00132	CcSEcCtD
Haloperidol—Dizziness—Epirubicin—bone cancer	0.000103	0.0013	CcSEcCtD
Haloperidol—Pruritus—Doxorubicin—bone cancer	0.000102	0.00129	CcSEcCtD
Haloperidol—Vomiting—Epirubicin—bone cancer	9.94e-05	0.00125	CcSEcCtD
Haloperidol—Nausea—Methotrexate—bone cancer	9.92e-05	0.00125	CcSEcCtD
Haloperidol—Diarrhoea—Doxorubicin—bone cancer	9.9e-05	0.00125	CcSEcCtD
Haloperidol—Rash—Epirubicin—bone cancer	9.86e-05	0.00124	CcSEcCtD
Haloperidol—Dermatitis—Epirubicin—bone cancer	9.85e-05	0.00124	CcSEcCtD
Haloperidol—Headache—Epirubicin—bone cancer	9.79e-05	0.00123	CcSEcCtD
Haloperidol—Dizziness—Doxorubicin—bone cancer	9.56e-05	0.00121	CcSEcCtD
Haloperidol—Nausea—Epirubicin—bone cancer	9.28e-05	0.00117	CcSEcCtD
Haloperidol—Loperamide—CYP3A4—bone cancer	9.27e-05	0.337	CrCbGaD
Haloperidol—Vomiting—Doxorubicin—bone cancer	9.2e-05	0.00116	CcSEcCtD
Haloperidol—Rash—Doxorubicin—bone cancer	9.12e-05	0.00115	CcSEcCtD
Haloperidol—Dermatitis—Doxorubicin—bone cancer	9.11e-05	0.00115	CcSEcCtD
Haloperidol—Headache—Doxorubicin—bone cancer	9.06e-05	0.00114	CcSEcCtD
Haloperidol—Nausea—Doxorubicin—bone cancer	8.59e-05	0.00108	CcSEcCtD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	4.19e-05	0.000424	CbGpPWpGaD
Haloperidol—DRD2—Circadian rythm related genes—JUN—bone cancer	4.18e-05	0.000423	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—NDUFA12—bone cancer	4.15e-05	0.00042	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—GNA11—bone cancer	4.14e-05	0.000419	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—IL3—bone cancer	4.13e-05	0.000418	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—NDUFA12—bone cancer	4.11e-05	0.000416	CbGpPWpGaD
Haloperidol—EBP—Metabolism—PTGS2—bone cancer	4.1e-05	0.000415	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—GRM1—bone cancer	4.08e-05	0.000413	CbGpPWpGaD
Haloperidol—DRD4—Circadian rythm related genes—TP53—bone cancer	4.06e-05	0.000411	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—IL3—bone cancer	4.03e-05	0.000408	CbGpPWpGaD
Haloperidol—CBR1—Metabolism—PTGS2—bone cancer	4.03e-05	0.000408	CbGpPWpGaD
Haloperidol—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.87e-05	0.000391	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—GRM1—bone cancer	3.85e-05	0.000389	CbGpPWpGaD
Haloperidol—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.82e-05	0.000386	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—IL3—bone cancer	3.8e-05	0.000385	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—GRM1—bone cancer	3.79e-05	0.000384	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—IL3—bone cancer	3.75e-05	0.00038	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—NT5C3A—bone cancer	3.74e-05	0.000378	CbGpPWpGaD
Haloperidol—DRD1—Circadian rythm related genes—TP53—bone cancer	3.66e-05	0.00037	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—NT5C3A—bone cancer	3.65e-05	0.000369	CbGpPWpGaD
Haloperidol—DRD3—Circadian rythm related genes—TP53—bone cancer	3.61e-05	0.000365	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—NDUFA12—bone cancer	3.51e-05	0.000356	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—GNA11—bone cancer	3.49e-05	0.000353	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—ENO2—bone cancer	3.48e-05	0.000352	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—SMO—bone cancer	3.46e-05	0.00035	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—NT5C3A—bone cancer	3.44e-05	0.000348	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—GNA11—bone cancer	3.43e-05	0.000347	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—GNA11—bone cancer	3.42e-05	0.000346	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—SMO—bone cancer	3.41e-05	0.000345	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—NT5C3A—bone cancer	3.41e-05	0.000345	CbGpPWpGaD
Haloperidol—GRIN2B—Developmental Biology—EGFR—bone cancer	3.4e-05	0.000344	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—SMO—bone cancer	3.4e-05	0.000344	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—RGS1—bone cancer	3.35e-05	0.000339	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—GRM4—bone cancer	3.35e-05	0.000339	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—GRM4—bone cancer	3.29e-05	0.000333	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—RGS1—bone cancer	3.29e-05	0.000333	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—GRM4—bone cancer	3.29e-05	0.000333	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—RGS1—bone cancer	3.29e-05	0.000333	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—DHFR—bone cancer	3.23e-05	0.000327	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—GNA11—bone cancer	3.17e-05	0.00032	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—IL3—bone cancer	3.16e-05	0.00032	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—SMO—bone cancer	3.12e-05	0.000316	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—GNA11—bone cancer	3.12e-05	0.000315	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—IL3—bone cancer	3.11e-05	0.000315	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—GNA11—bone cancer	3.11e-05	0.000315	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—IL3—bone cancer	3.1e-05	0.000314	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	3.1e-05	0.000314	CbGpPWpGaD
Haloperidol—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	3.07e-05	0.00031	CbGpPWpGaD
Haloperidol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	3.06e-05	0.00031	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—SMO—bone cancer	3.06e-05	0.000309	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—GNA11—bone cancer	3.02e-05	0.000305	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—SMO—bone cancer	3.01e-05	0.000305	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.99e-05	0.000303	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—ENO2—bone cancer	2.93e-05	0.000296	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—NT5C3A—bone cancer	2.91e-05	0.000295	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—GRM1—bone cancer	2.9e-05	0.000294	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—SMO—bone cancer	2.87e-05	0.000291	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—IL3—bone cancer	2.87e-05	0.000291	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—GNA11—bone cancer	2.86e-05	0.000289	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—GRM1—bone cancer	2.86e-05	0.000289	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—GRM1—bone cancer	2.85e-05	0.000288	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—IL3—bone cancer	2.82e-05	0.000286	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—IL3—bone cancer	2.82e-05	0.000285	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—GNA11—bone cancer	2.8e-05	0.000283	CbGpPWpGaD
Haloperidol—DRD2—Circadian rythm related genes—TP53—bone cancer	2.76e-05	0.000279	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—GNA11—bone cancer	2.75e-05	0.000279	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—CYP3A4—bone cancer	2.74e-05	0.000277	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.72e-05	0.000276	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—DHFR—bone cancer	2.72e-05	0.000275	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—NDUFA12—bone cancer	2.71e-05	0.000274	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—SMO—bone cancer	2.71e-05	0.000274	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.7e-05	0.000273	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—SMO—bone cancer	2.67e-05	0.00027	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—ATF1—bone cancer	2.66e-05	0.000269	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—GNA11—bone cancer	2.63e-05	0.000266	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—ATF1—bone cancer	2.6e-05	0.000263	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IL3—bone cancer	2.59e-05	0.000262	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—ATF1—bone cancer	2.56e-05	0.000259	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—GNA11—bone cancer	2.54e-05	0.000257	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IL3—bone cancer	2.54e-05	0.000257	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IL3—bone cancer	2.5e-05	0.000253	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—GNA11—bone cancer	2.48e-05	0.000251	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—GNA11—bone cancer	2.44e-05	0.000247	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—ATF1—bone cancer	2.44e-05	0.000247	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IL3—bone cancer	2.38e-05	0.000241	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—GSTP1—bone cancer	2.34e-05	0.000237	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—ATF1—bone cancer	2.3e-05	0.000233	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—CYP3A4—bone cancer	2.3e-05	0.000233	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—ATF1—bone cancer	2.27e-05	0.00023	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—NT5C3A—bone cancer	2.25e-05	0.000227	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IL3—bone cancer	2.25e-05	0.000227	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IL3—bone cancer	2.22e-05	0.000224	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TGFBR2—bone cancer	2.21e-05	0.000224	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TGFBR2—bone cancer	2.17e-05	0.000219	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TGFBR2—bone cancer	2.13e-05	0.000216	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.12e-05	0.000215	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—ENO2—bone cancer	2.12e-05	0.000214	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IGF1R—bone cancer	2.08e-05	0.000211	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—SMO—bone cancer	2.05e-05	0.000207	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IGF1R—bone cancer	2.04e-05	0.000206	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TGFBR2—bone cancer	2.04e-05	0.000206	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—SMO—bone cancer	2.01e-05	0.000204	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—SMO—bone cancer	2.01e-05	0.000203	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IGF1R—bone cancer	2.01e-05	0.000203	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—ENO2—bone cancer	2e-05	0.000202	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—GSTP1—bone cancer	1.97e-05	0.000199	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—DHFR—bone cancer	1.96e-05	0.000199	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TGFBR2—bone cancer	1.92e-05	0.000194	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IGF1R—bone cancer	1.92e-05	0.000194	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TGFBR2—bone cancer	1.9e-05	0.000192	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—GNA11—bone cancer	1.87e-05	0.000189	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—DHFR—bone cancer	1.86e-05	0.000188	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—GNA11—bone cancer	1.84e-05	0.000186	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—GNA11—bone cancer	1.84e-05	0.000186	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—GNA11—bone cancer	1.84e-05	0.000186	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IGF1R—bone cancer	1.81e-05	0.000183	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IGF1R—bone cancer	1.78e-05	0.00018	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.78e-05	0.00018	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—ATF1—bone cancer	1.74e-05	0.000176	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—GNA11—bone cancer	1.73e-05	0.000175	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—ATF1—bone cancer	1.71e-05	0.000173	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—ATF1—bone cancer	1.71e-05	0.000173	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL3—bone cancer	1.7e-05	0.000172	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL3—bone cancer	1.67e-05	0.000169	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL3—bone cancer	1.67e-05	0.000169	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—CYP3A4—bone cancer	1.66e-05	0.000168	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—ENO2—bone cancer	1.64e-05	0.000166	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—ENO2—bone cancer	1.6e-05	0.000162	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—CYP3A4—bone cancer	1.57e-05	0.000159	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.56e-05	0.000158	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—DHFR—bone cancer	1.52e-05	0.000154	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—KIT—bone cancer	1.51e-05	0.000153	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—ENO2—bone cancer	1.51e-05	0.000152	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—ENO2—bone cancer	1.49e-05	0.000151	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—DHFR—bone cancer	1.48e-05	0.00015	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—KIT—bone cancer	1.48e-05	0.00015	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—KIT—bone cancer	1.46e-05	0.000147	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TGFBR2—bone cancer	1.45e-05	0.000147	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TGFBR2—bone cancer	1.43e-05	0.000144	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TGFBR2—bone cancer	1.42e-05	0.000144	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—GSTP1—bone cancer	1.42e-05	0.000144	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—BRAF—bone cancer	1.42e-05	0.000144	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—GNA11—bone cancer	1.42e-05	0.000144	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—DHFR—bone cancer	1.4e-05	0.000141	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—BRAF—bone cancer	1.39e-05	0.000141	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—KIT—bone cancer	1.39e-05	0.000141	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—GNA11—bone cancer	1.38e-05	0.00014	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—DHFR—bone cancer	1.38e-05	0.00014	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—EGFR—bone cancer	1.38e-05	0.000139	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—BRAF—bone cancer	1.37e-05	0.000139	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IGF1R—bone cancer	1.36e-05	0.000138	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—EGFR—bone cancer	1.35e-05	0.000136	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—GSTP1—bone cancer	1.34e-05	0.000136	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IGF1R—bone cancer	1.34e-05	0.000136	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IGF1R—bone cancer	1.34e-05	0.000136	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—EGFR—bone cancer	1.33e-05	0.000134	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—KIT—bone cancer	1.31e-05	0.000133	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—BRAF—bone cancer	1.31e-05	0.000132	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—GNA11—bone cancer	1.31e-05	0.000132	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—GNA11—bone cancer	1.29e-05	0.000131	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—KIT—bone cancer	1.29e-05	0.000131	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CYP3A4—bone cancer	1.29e-05	0.00013	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.28e-05	0.00013	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ENO2—bone cancer	1.28e-05	0.000129	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—EGFR—bone cancer	1.27e-05	0.000128	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CYP3A4—bone cancer	1.26e-05	0.000127	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—BRAF—bone cancer	1.23e-05	0.000125	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—BRAF—bone cancer	1.22e-05	0.000123	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PTGS2—bone cancer	1.21e-05	0.000123	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—EGFR—bone cancer	1.19e-05	0.000121	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—MDM2—bone cancer	1.19e-05	0.00012	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CYP3A4—bone cancer	1.18e-05	0.00012	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—DHFR—bone cancer	1.18e-05	0.00012	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—EGFR—bone cancer	1.18e-05	0.000119	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CYP3A4—bone cancer	1.17e-05	0.000119	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.17e-05	0.000118	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MDM2—bone cancer	1.17e-05	0.000118	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MDM2—bone cancer	1.15e-05	0.000116	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GNA11—bone cancer	1.11e-05	0.000112	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—GSTP1—bone cancer	1.1e-05	0.000111	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MDM2—bone cancer	1.09e-05	0.000111	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—GSTP1—bone cancer	1.07e-05	0.000109	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—JUN—bone cancer	1.03e-05	0.000105	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MDM2—bone cancer	1.03e-05	0.000104	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PTGS2—bone cancer	1.02e-05	0.000103	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MDM2—bone cancer	1.02e-05	0.000103	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—JUN—bone cancer	1.01e-05	0.000103	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—GSTP1—bone cancer	1.01e-05	0.000102	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—MMP9—bone cancer	1.01e-05	0.000102	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—GSTP1—bone cancer	1e-05	0.000102	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CYP3A4—bone cancer	1e-05	0.000101	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.97e-06	0.000101	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—JUN—bone cancer	9.97e-06	0.000101	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—KIT—bone cancer	9.9e-06	0.0001	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MMP9—bone cancer	9.86e-06	9.97e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ENO2—bone cancer	9.84e-06	9.96e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—KIT—bone cancer	9.74e-06	9.86e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—KIT—bone cancer	9.72e-06	9.83e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MMP9—bone cancer	9.7e-06	9.81e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—JUN—bone cancer	9.52e-06	9.63e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—BRAF—bone cancer	9.3e-06	9.41e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MMP9—bone cancer	9.26e-06	9.37e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—BRAF—bone cancer	9.15e-06	9.26e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—BRAF—bone cancer	9.13e-06	9.24e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—DHFR—bone cancer	9.13e-06	9.24e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—EGFR—bone cancer	9.02e-06	9.13e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—JUN—bone cancer	8.97e-06	9.08e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—EGFR—bone cancer	8.87e-06	8.98e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—JUN—bone cancer	8.85e-06	8.96e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—EGFR—bone cancer	8.85e-06	8.96e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MMP9—bone cancer	8.73e-06	8.84e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MMP9—bone cancer	8.61e-06	8.72e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GSTP1—bone cancer	8.57e-06	8.67e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GNA11—bone cancer	8.53e-06	8.63e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—EGFR—bone cancer	8.13e-06	8.23e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—EGFR—bone cancer	7.96e-06	8.06e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—EGFR—bone cancer	7.84e-06	7.93e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MDM2—bone cancer	7.8e-06	7.89e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MDM2—bone cancer	7.67e-06	7.76e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MDM2—bone cancer	7.65e-06	7.74e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—EGFR—bone cancer	7.48e-06	7.57e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTGS2—bone cancer	7.37e-06	7.46e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—EGFR—bone cancer	7.06e-06	7.14e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTGS2—bone cancer	6.97e-06	7.05e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—EGFR—bone cancer	6.96e-06	7.04e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TP53—bone cancer	6.83e-06	6.91e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—JUN—bone cancer	6.78e-06	6.86e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TP53—bone cancer	6.69e-06	6.77e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—JUN—bone cancer	6.67e-06	6.75e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—JUN—bone cancer	6.65e-06	6.73e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTP1—bone cancer	6.62e-06	6.69e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MMP9—bone cancer	6.59e-06	6.67e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TP53—bone cancer	6.58e-06	6.66e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MMP9—bone cancer	6.49e-06	6.56e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MMP9—bone cancer	6.47e-06	6.55e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TP53—bone cancer	6.28e-06	6.36e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TP53—bone cancer	5.92e-06	5.99e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TP53—bone cancer	5.85e-06	5.91e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTGS2—bone cancer	5.7e-06	5.77e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTGS2—bone cancer	5.56e-06	5.63e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—EGFR—bone cancer	5.33e-06	5.39e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTGS2—bone cancer	5.24e-06	5.3e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—EGFR—bone cancer	5.24e-06	5.3e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—EGFR—bone cancer	5.23e-06	5.29e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTGS2—bone cancer	5.2e-06	5.26e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TP53—bone cancer	4.47e-06	4.53e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTGS2—bone cancer	4.44e-06	4.49e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TP53—bone cancer	4.4e-06	4.45e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TP53—bone cancer	4.39e-06	4.44e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTGS2—bone cancer	3.43e-06	3.47e-05	CbGpPWpGaD
